Company Overview of Lycera Corporation
Lycera Corporation, a pharmaceutical company, engages in the discovery and development of small-molecule immunomodulators for the treatment of patients with autoimmune diseases. It offers products for the treatment of diseases, such as psoriasis, rheumatoid arthritis, lupus erythematosis, inflammatory bowel disease, and transplant rejection. Lycera Corporation was founded in 2006 and is headquartered in Plymouth, Michigan with a research and development center in Ann Arbor, Michigan.
46701 North Commerce Center Drive
Plymouth, MI 48170
Founded in 2006
Key Executives for Lycera Corporation
Co-Founder and Member of the Scientific Advisory Board
Senior Vice President of Corporate Development and Strategy
Senior Vice President of Biology
Compensation as of Fiscal Year 2014.
Lycera Corporation Key Developments
Lycera Corp. Announces Research Showing Novel, Oral Immunotherapy Possesses Potent Single Agent Anti-Cancer Activity
Nov 7 14
Lycera Corp. announced that data on the anti-tumor activity of the company's novel synthetic RORgamma agonist product candidates were presented at the Society for Immunotherapy of Cancer (SITC) annual meeting being held in National Harbor, MD. The research findings demonstrate that RORgamma agonists reprogram immune cells to enhance their activity and survival as well as decrease immunosuppressive mechanisms in the tumor that can limit the efficacy of cancer immunotherapies. Collectively, these activities result in decreased tumor growth and significantly enhanced survival in animal models of cancer. As a result, researchers conclude modulation of the immune system by RORgamma agonists may provide significant anti-tumor benefits in treatment of a range of cancers. According to the study results, RORgamma small molecule agonists effectively increase immune activation mechanisms, such as enhanced cytokine production from murine and human cells. They also decrease immune suppression mechanisms as demonstrated by favorable changes in effector T cell to Treg cell ratios and by reduced PD-1 expression and cell desensitization to checkpoint inhibition. Highlighting potential utility in adoptive cell therapy systems, enhanced tumor growth control is observed following the addition of RORgamma agonists to T cell expansion cocktails. Recent research has further shown that oral delivery of RORgamma agonists exhibits single agent activity with a demonstrated increase in survival in the MC38 colon cancer model. As a result, oral RORgamma agonists as monotherapy may have the potential to inhibit tumor growth and increase long term survival.
Lycera Appoints Harinder Singh as Chair of Scientific Advisory Board
Aug 8 14
Lycera Corp. announced the appointment of Harinder Singh, Ph.D., as chair of the company’s scientific advisory board. Dr. Singh will lead the board’s efforts to provide guidance and insight to advance Lycera’s multiple ongoing research programs and pipeline of therapies targeting unmet needs in the treatment of autoimmune disease and cancer. Dr. Singh has more than 25 years of scientific research and academic experience in the fields of Molecular Biology and Immunology. He is currently Director of the Division of Immunobiology and the Center for Systems Immunology at Cincinnati Children’s Hospital Medical Center.
Lycera Corporation Presents at 8th Annual BIO Europe Spring 2014, Mar-11-2014 10:30 AM
Jan 21 14
Lycera Corporation Presents at 8th Annual BIO Europe Spring 2014, Mar-11-2014 10:30 AM. Venue: OVAL Lingotto, Turin, Italy.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 21, 2014
Most Searched Private Companies
Sponsored Financial Commentaries